Paper Type
ERF
Abstract
Understanding the therapeutic effects of diabetes medications is an essential aspect of ongoing care for maintaining wellness and reducing early readmission (< 30 days). We analysed comorbid diabetic patients to establish the impacts of medication dosage on their readmission predisposition. After statistically analysing 101,766 patients’ records with Analysis of Variance (ANOVA), Students’ t-test with Bonferroni-Holm correction, and multivariate logistics regression, we affirmed that metformin, insulin, and repaglinide administered dosages significantly influence readmission at 95% confidence level. This result shows that therapeutic dosages influence “< 30 days” and “No” readmissions for those treated with insulin and metformin while those treated with repaglinide are impacted on “< 30 days” and “> 30 days” readmissions. This finding opens a new frontier to study the factors influencing unplanned readmissions for comorbid diabetic patients treated with these medications.
Recommended Citation
Ossai, Chinedu and Wickramasinghe, Nilmini, "An Assessment of Medication Therapy and Readmission of Comorbid Diabetic Patients" (2020). AMCIS 2020 Proceedings. 4.
https://aisel.aisnet.org/amcis2020/data_science_analytics_for_decision_support/data_science_analytics_for_decision_support/4
An Assessment of Medication Therapy and Readmission of Comorbid Diabetic Patients
Understanding the therapeutic effects of diabetes medications is an essential aspect of ongoing care for maintaining wellness and reducing early readmission (< 30 days). We analysed comorbid diabetic patients to establish the impacts of medication dosage on their readmission predisposition. After statistically analysing 101,766 patients’ records with Analysis of Variance (ANOVA), Students’ t-test with Bonferroni-Holm correction, and multivariate logistics regression, we affirmed that metformin, insulin, and repaglinide administered dosages significantly influence readmission at 95% confidence level. This result shows that therapeutic dosages influence “< 30 days” and “No” readmissions for those treated with insulin and metformin while those treated with repaglinide are impacted on “< 30 days” and “> 30 days” readmissions. This finding opens a new frontier to study the factors influencing unplanned readmissions for comorbid diabetic patients treated with these medications.
When commenting on articles, please be friendly, welcoming, respectful and abide by the AIS eLibrary Discussion Thread Code of Conduct posted here.